Literature DB >> 31287348

Comparison between flow cytometry and standard PCR in the evaluation of MRD in children with acute lymphoblastic leukemia treated with the GBTLI LLA - 2009 protocol.

Juliana Maria Camargos Rocha1, Sandra Guerra Xavier1, Marcelo Eduardo de Lima Souza1, Mitiko Murao1, Benigna Maria de Oliveira1.   

Abstract

Minimal residual disease (MRD) monitoring is of prognostic importance in childhood acute lymphoblastic leukemia (ALL). The detection of immunoglobulin and T-cell receptor gene rearrangements by real-time quantitative PCR (RT-PCR) is considered the gold standard for this evaluation. However, more accessible methods also show satisfactory performance. This study aimed to compare MRD analysis by four-color flow cytometry (FC) and qualitative standard PCR on days 35 and 78 of chemotherapy and to correlate these data with patients' clinical characteristics. Forty-two children with a recent diagnosis of ALL, admitted to a public hospital in Brazil for treatment in accordance with the Brazilian Childhood Cooperative Group for ALL Treatment (GBTLI LLA-2009), were included. Bone marrow samples collected at diagnosis and on days 35 and 78 of treatment were analyzed for the immunophenotypic characterization of blasts by FC and for the detection of clonal rearrangements by standard PCR. Paired analyses were performed in 61/68 (89.7%) follow-up samples, with a general agreement of 88.5%. Disagreements were resolved by RT-PCR, which evidenced one false-negative and four false-positive results in FC, as well as two false-negative results in PCR. Among the prognostic factors, a significant association was found only between T-cell lineage and MRD by standard PCR. These results show that FC and standard PCR produce similar results in MRD detection of childhood ALL and that both methodologies may be useful in the monitoring of disease treatment, especially in regions with limited financial resources.

Entities:  

Keywords:  Acute lymphoblastic leukemia; IG/TR gene rearrangements; flow cytometry; minimal residual disease; polymerase chain reaction

Year:  2019        PMID: 31287348     DOI: 10.1080/08880018.2019.1636168

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

Review 1.  Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies.

Authors:  Md Salman Shakil; Mahruba Sultana Niloy; Kazi Mustafa Mahmud; Mohammad Amjad Kamal; Md Asiful Islam
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

2.  Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.

Authors:  Liang Chen; Huai-Xiu Yan; Xiao-Wei Liu; Wen-Xin Chen
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.817

3.  Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia.

Authors:  Joanna Zawitkowska; Monika Lejman; Michał Romiszewski; Michał Matysiak; Magdalena Ćwiklińska; Walentyna Balwierz; Joanna Owoc-Lempach; Bernarda Kazanowska; Katarzyna Derwich; Jacek Wachowiak; Maciej Niedźwiecki; Elżbieta Adamkiewicz-Drożyńska; Joanna Trelińska; Wojciech Młynarski; Andrzej Kołtan; Mariusz Wysocki; Renata Tomaszewska; Tomasz Szczepański; Marcin Płonowski; Maryna Krawczuk-Rybak; Justyna Urbańska-Rakus; Katarzyna Machnik; Tomasz Ociepa; Tomasz Urasiński; Agnieszka Mizia-Malarz; Grażyna Sobol-Milejska; Grażyna Karolczyk; Jerzy Kowalczyk
Journal:  Sci Rep       Date:  2020-11-19       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.